The acute vascular effects of frusemide in heart failure

British Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2000, Pages 9-13

  Jhund, Pardeep S ^a   McMurray, John J V ^a   Davie, Andrew P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; LOOP DIURETIC AGENT;

ARTERY CONSTRICTION; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; PRIORITY JOURNAL; REVIEW; VEIN DILATATION;

ARTERIES; DIURETICS; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; VEINS;

EID: 0034084851     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00219.x     Document Type: Review

References (33)

1. 1 Weinstein FR, Solis-Gil V. The treatment of acute pulmonary edema with frusemide. Curr Ther Res 1966; 8: 435-440.
2. 2 Biagi RW, Bapat BN. Frusemide in acute pulmonary oedema. Lancet 1967; i: 849.
3. 3 Bhatia ML, Singh I, Manchanda SC, Khanna PK, Roy SB. Effect of frusemide on pulmonary blood Volume. Br Med J 1969; 2: 551-552.
4. 4 Dikshit K, Vyden JK, Forrester JS, Chaterjee K, Prakash P, Swan HJC. Renal and extrarenal haemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973; 288: 1087-1090.
5. 5 Franciosa JA, Silverstein SR. Haemodynamic effects of nitroprusside and furosemide in left ventricular failure. Clin Pharmacol Ther 1982; 32: 62-69.
6. 6 Johnston GD, Nicholls DP, Kondowe GB, Finch MB. Comparison of the acute vascular effects of frusemide and bumetanide. Br J Clin Pharmacol 1986; 21: 359-364.
7. 7 Johnston GD, Nicholls DP, Leahey WJ. The dose-response characteristics of the acute non-diuretic peripheral vascular effects of frusemide in normal subjects. Br J Clin Pharmacol 1984; 18: 75-81.
8. 8 Pickkers P, Dormans TPJ, Russel FGM, et al. Direct vascular effects of furosemide in humans. Circulation 1997; 96: 1847-1852.
9. 9 Johnston GD, O'Conner PC, Nicholls DP, Leahey WJ, Finch MB. The effects of propranolol and digoxin on the acute vascular responses to frusemide in normal man. Br J Clin Pharmacol 1985; 19: 417-421.
10. 10 Valette H, Duhaze P, Apoil E. Plethysmographic studies with frusemide and piretanide in healthy volunteers. Br J Clin Pharmacol 1979; 7: 219.
11. 11 Harada K, Ohmori M, Fujimura A, Ohashi K. No evidence of a direct venodilatory effect of furosemide in healthy human subjects. J Clin Pharmacol 1996; 36: 271-273.
12. 12 Francis GS, Siegal RM, Goldsmith SR, Olivari MT, Levine B, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Int Med 1985; 103: 1-6.
13. 13 Kiely DG, Cargill RI, Lipworth BJ. Effects of frusemide and hypoxia on the pulmonary vascular bed in man. Br J Clin Pharmacol 1997; 43: 309-313.
14. 14 Wilson TW, McCauley FA, Wells HD. Effects of low-dose aspirin on responses to furosemide. J Clin Pharmacol 1986; 26: 100-105.
15. 15 Johnston GD, Hiatt WR, Nies AS, Payne A, Murphy RC, Gerber JG. Factors modifying the early nondiuretic vascular effects of furosemide in man. Circ Res 1983; 53: 630-635.
16. 16 Goldiner WH, Valente WA, Hamilton BP, Mersey JH. The effect of prostaglandin inhibition on renin release. J Lab Clin Med 1981; 98: 929-937.
17. 17 MacKay IG, Muir AL, Watson ML. Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man. Br J Clin Pharmacol 1984; 17: 513-519.
18. 18 Tan SY, Mulrow PJ. Inhibition of the renin-aldosterone response to furosemide by indomethacin. J Clin Endocrinol Metab 1977; 45: 174-176.
19. 19 Johnston GD, Nicholls DP, Leahey WJ, Finch MB. The effects of captopril on the acute vascular responses to frusemide in man. Clin Sci 1983; 65: 359-363.
20. 20 Goldsmith SR, Francis G, Cohn JN. Attenuation of the pressor response to intravenous frusemide by angiotensin converting enzyme inhibition in congestive heart failure. Am J Cardiol 1989; 64: 1382-1385.
21. 21 Barker JE, Anderson J, Treasure T, Piper PJ. Influence of endothelium and surgical preparation on responses of human saphenous vein and internal thoracic artery to angiotensin II. Br J Clin Pharmacol 1994; 38: 57-62.
22. 22 De Pasquale NP, Burch GE. Effect of angiotensin II on the intact forearm veins of man. Circ Res 1963; 13: 239-245.
23. 23 Stanke F, Devillier P, Breant D, et al. Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle. Br J Clin Pharmacol 1998; 46: 571-575.
24. 24 Baan J, Chang PC, Vermeij P, Pfaffendorf M, van Zweiten PA. Venoconstriction by angiotensin II in the human forearm is inhibited by losartan but not by nicardipine. J Cardiovasc Pharmacol 1998; 31: 50-55.
25. 25 Newby DE, Masamouri S, Johnston NR, Boon NA, Webb DJ. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. Cardoivasc Res 1997; 36: 268-275.
26. 26 Newby DE, Goodfield NER, Flapan AD, Boon NA, Fox KAA, Webb DJ. Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II. Heart 1998; 80: 134-141.
27. 27 Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993; 33: R917-R923.
28. 28 Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin type-2 receptor gene in mice. Nature 1995; 377: 744-747.
29. 29 Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin rype-2 receptor. Nature 1995; 377: 748-750.
30. 30 Gimbrone MA, Alexander RW. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science 1975; 189: 219-220.
31. 31 Ellory JC, Stewart CW. The human erythrocyte Cl-dependent Na-K cotransport system as a possible model for studying the action of loop diuretics. Br J Pharmacol 1982; 75: 183-188.
32. 32 Ferrari M. Effects of digoxin and digoxin plus furosemide on the plasma renin activity of hypertensive patients. Circ Res 1979; 44: 295.
33. 33 Bravo EL, Tarazi RC, Dustan H. On the mechanism of suppressed plasma-renin activity during β-adrenergic blockade with propanolol. J Lab Clin Med 1974; 83: 119-128.